ALXN News and Press, Alexion Pharmaceuticals Inc. From 08/30/19

Ulta Beauty (NASDAQ: ULTA )  -25%  on Q2 earnings . More news on: Ulta Beauty, Inc., American Outdoor Brands Corporation, Alexion Pharmaceuticals, Inc., Stocks on the move, Read more ...

- Five abstracts accepted, including new long-term data from PREVENT trial of SOLIRIS ® (eculizumab) in adults with anti-AQP4 antibody-positive NMOSD - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that five abstracts from the Phase 3 PREVENT study of SOLIRIS ...

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 14th Annual Citi Biotech Conference in Boston, MA on Wednesday, September 4th, 2019 at 12:00 p.m., ET. An audio webcast of the presentation will be available live. You can access the webcast at: htt...

Overview/Thesis: Over this past week, Amgen ( AMGN ) was rumored to be interested in buying out Alexion ( ALXN ), the biotech leader in developing treatments for diseases of the complement system, for over $40 billion. Ignored in the hubbub over that rumor was the fact that there simultane...

As expected, the European Commission approves Alexion Pharmaceuticals' (NASDAQ: ALXN ) Soliris (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease. ...

  - SOLIRIS ® (eculizumab) is the first and only approved medication for NMOSD in Europe - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving placebo at 48 weeks - Alexion Pharmaceutica...

Stop! My original title for this morning's piece was Stop Selling! That's because the futures were down very hard last night. If you are in the habit of selling on political news over this president's tweets, you have lost money. If you sold Friday and want to buy this morning because the ...

Biotech investors have been predicting Amgen 's (NASDAQ: AMGN) potential purchase of  Alexion Pharmaceuticals (NASDAQ: ALXN) for over a year, and the rumor has picked up steam following signals that the big biotech is ready to make some deals.  At a rumored offering price of $20...

Is a major biotech buyout in the works? Spanish television network Intereconomia recently reported that Amgen (NASDAQ: AMGN) is in discussions to acquire Alexion Pharmaceuticals (NASDAQ: ALXN) . Intereconomia cited unnamed sources that said a deal could be announced soon, with Amgen pot...

A potential deal for Amgen (NASDAQ: AMGN ) to buy Alexion Pharmaceuticals (NASDAQ: ALXN ) “would be highly accretive,” Mizuho says. More news on: Amgen Inc., Alexion Pharmaceuticals, Inc., Merger & acquisition news, Stocks on the move, Healthcare stocks news, Read mor...